Literature DB >> 26822157

Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis.

F M Watzka1, C Fottner2, M Miederer3, M M Weber2, A Schad4, H Lang1, T J Musholt5.   

Abstract

BACKGROUND: Neuroendocrine Neoplasms of the small intestine have been noticed more frequently over the past 35 years. They constitute about 25% of all NENs and 29% of all tumors of the small intestine. Due to the predominantly indolent nature and overall good prognosis, the benefit of surgical treatment is still debated.
METHODS: In a retrospective study, data of 83 surgically treated patients with neuroendocrine neoplasms of the small intestine, 48 males and 35 females with a median age of 62 years (range 25-86 years) were analyzed. Patient data were documented in the MaDoc database for neuroendocrine tumors of the University Medical Center of Mainz. IBM SPSS Statistics 20 was used for statistical analysis. Kaplan-Meier survival curves and Log-Rank tests, censoring patients at the time of last follow-up, were used to compare the overall survival depending on potential prognostic factors (stage, grade, surgical treatment).
RESULTS: At the time of diagnoses, the most common clinical symptoms were abdominal pain (n = 31, 37.3%), bowel obstruction (n = 11, 13.3%), bowel perforation and peritonitis (n = 3, 3.6%), gastrointestinal bleeding (n = 9, 10.8%), weight loss (n = 11, 13.3%), and carcinoid syndrome (n = 27, 32.5%). 65 patients (78.3%) had lymph node metastasis and in 58 patients (69.9%) distant metastasis were present. Segmental bowel resection (44) was the most common surgical procedure, followed by right hemi-colectomy (32) and explorative laparotomy (7). In most patients (78.9%), lymphadenectomy (systematic/selective) was performed. The 5-year survival of patients who underwent a systematic or a selective lymphadenectomy differed significantly (82.2 vs. 40.0%). The overall 3-, 5-, and 10-year survival rates were 88.2, 80.3, and 71.0%, respectively.
CONCLUSION: Mesenteric lymph node metastases are almost invariably present and have significant impact on patients' prognosis. Systematic lymphadenectomy prevents complications and improves the survival. Early surgical treatment should be the goal in order to prevent complications.

Entities:  

Mesh:

Year:  2016        PMID: 26822157     DOI: 10.1007/s00268-016-3432-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

Review 1.  Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors.

Authors:  Florencia G Que; Juan M Sarmiento; David M Nagorney
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

2.  Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors.

Authors:  Christine S Landry; Heather Y Lin; Alexandria Phan; Chusilp Charnsangavej; Eddie K Abdalla; Thomas Aloia; J Nicolas Vauthey; Matthew H G Katz; James C Yao; Jason B Fleming
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

3.  Management of disseminated midgut carcinoid tumours.

Authors:  H Ahlman; B Wängberg; S Jansson; O Stenqvist; K Geterud; U Tylén; K Caidahl; T Scherstén; L E Tisell
Journal:  Digestion       Date:  1991       Impact factor: 3.216

Review 4.  [Extent of resection for neuroendocrine tumors of the small intestine].

Authors:  T J Musholt
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

5.  Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.

Authors:  Henning Jann; Stephanie Roll; Anne Couvelard; Olivia Hentic; Marianne Pavel; Jacqueline Müller-Nordhorn; Martin Koch; Christoph Röcken; Guido Rindi; Philippe Ruszniewski; Bertram Wiedenmann; Ulrich-Frank Pape
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

6.  Method for dissection of mesenteric metastases in mid-gut carcinoid tumors.

Authors:  U Ohrvall; B Eriksson; C Juhlin; S Karacagil; J Rastad; P Hellman; G Akerström
Journal:  World J Surg       Date:  2000-11       Impact factor: 3.352

7.  A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients.

Authors:  Christine S Landry; Guy Brock; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  Am J Surg       Date:  2008-12       Impact factor: 2.565

8.  Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.

Authors:  Karl Y Bilimoria; David J Bentrem; Jeffrey D Wayne; Clifford Y Ko; Charles L Bennett; Mark S Talamonti
Journal:  Ann Surg       Date:  2009-01       Impact factor: 12.969

9.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.

Authors:  Ulrich-Frank Pape; Henning Jann; Jacqueline Müller-Nordhorn; Angelina Bockelbrink; Uta Berndt; Stefan N Willich; Martin Koch; Christoph Röcken; Guido Rindi; Bertram Wiedenmann
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

Review 10.  Biology and management of the midgut carcinoid.

Authors:  M D Basson; H Ahlman; B Wangberg; I M Modlin
Journal:  Am J Surg       Date:  1993-02       Impact factor: 2.565

View more
  16 in total

1.  Prognostic Factors in Curative Resected Locoregional Small Intestine Neuroendocrine Neoplasms.

Authors:  Maximilian Evers; Anja Rinke; Johannes Rütz; Annette Ramaswamy; Elisabeth Maurer; Detlef K Bartsch
Journal:  World J Surg       Date:  2021-01-08       Impact factor: 3.352

2.  Optimal Lymphadenectomy in Small Bowel Neuroendocrine Tumors: Analysis of the NCDB.

Authors:  Benjamin M Motz; Patrick D Lorimer; Danielle Boselli; Joshua S Hill; Jonathan C Salo
Journal:  J Gastrointest Surg       Date:  2017-08-17       Impact factor: 3.452

Review 3.  [Surgical aspects of neuroendocrine tumors of the small intestine].

Authors:  F Weber; H Dralle
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

Review 4.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

Review 5.  Extent of Lymph Node Dissection for Small Bowel Neuroendocrine Tumors.

Authors:  Julie Hallet; Calvin Law
Journal:  World J Surg       Date:  2020-07-31       Impact factor: 3.352

6.  Carcinoid Tumor: Advances in Treatment Options.

Authors:  Urwat T Vusqa; Stuti Patel; Mamoon Ur Rashid; Deepika Sarvepalli; Abu H Khan
Journal:  Cureus       Date:  2020-01-13

7.  Management of Locally Advanced and Unresectable Small Bowel Neuroendocrine Tumours.

Authors:  Jonathan Koea
Journal:  World J Surg       Date:  2020-08-28       Impact factor: 3.352

8.  Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors.

Authors:  Mohammad Y Zaidi; Alexandra G Lopez-Aguiar; Mary Dillhoff; Eliza Beal; George Poultsides; Eleftherios Makris; Flavio Rocha; Angelena Crown; Kamran Idrees; Paula Marincola Smith; Hari Nathan; Megan Beems; Daniel Abbott; James R Barrett; Ryan C Fields; Jesse Davidson; Kenneth Cardona; Shishir K Maithel
Journal:  JAMA Surg       Date:  2019-02-01       Impact factor: 14.766

9.  Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database.

Authors:  Chintan P Shah; Lazarus K Mramba; Rohit Bishnoi; Athira Unnikrishnan; Jennifer M Duff; Sreenivasa R Chandana
Journal:  J Gastrointest Oncol       Date:  2019-10

Review 10.  The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Ann Surg Oncol       Date:  2021-01-15       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.